SCHEDULE: Wellington Management Maintains 8.9% Stake in Crinetics

Wellington Management Group LLP and its affiliates reported continued beneficial ownership of 8.9% of Crinetics Pharmaceuticals, Inc.'s common stock as of September 30, 2025.

Summary

• Wellington Management Group LLP, along with its affiliated entities, reported beneficial ownership of 8,381,991 shares of Crinetics Pharmaceuticals, Inc. common stock.
• This aggregate amount represents 8.9% of the issuer's class of common stock.
• The reporting persons, including Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP, each hold shared voting power over 7,386,849 shares and shared dispositive power over 8,381,991 shares.
• Wellington Management Company LLP, an investment adviser, holds shared voting power over 7,344,228 shares and shared dispositive power over 7,928,191 shares, contributing to the overall aggregate beneficial ownership.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. It confirms a significant, passive institutional stake, which can be viewed as a vote of confidence. However, it does not introduce new information that would drastically alter the company's outlook or valuation.

Positives

• Continued significant institutional ownership by Wellington Management Group LLP and its affiliates, indicating ongoing confidence in Crinetics Pharmaceuticals, Inc.

Future Outlook

This filing does not contain forward-looking statements or guidance from the issuer or the reporting entity regarding future performance or strategic direction.

Industry Context

Institutional investment in biotechnology companies like Crinetics Pharmaceuticals is common, reflecting investor interest in the sector's potential for innovation and growth. Wellington Management's continued significant stake suggests a long-term investment perspective within the pharmaceutical industry.

Stakeholder Impact

• Shareholders may view the continued significant institutional holding by Wellington Management as a positive signal of long-term investor confidence in Crinetics Pharmaceuticals, Inc.

Key Dates

Recommendation

The filing is a routine Schedule 13G amendment reporting beneficial ownership by a large institutional investor. While the continued significant stake by Wellington Management indicates confidence, this type of filing does not provide new operational, financial, or strategic information that would warrant a change from a 'hold' recommendation based solely on its content. Investors should look to the company's financial reports and operational updates for more comprehensive investment decision-making.

Keywords

Crinetics Pharmaceuticals, Wellington Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals